List of Nurtec Odt drug patents
Nurtec Odt is owned by Biohaven Ireland.
Nurtec Odt contains Rimegepant Sulfate.
Nurtec Odt has a total of 3 drug patents out of which 0 drug patents have expired.
Nurtec Odt was authorised for market use on 27 February, 2020.
Nurtec Odt is available in tablet, orally disintegrating;oral dosage forms.
Nurtec Odt can be used as acute treatment of migraine with or without aura in adults; preventive treatment of episodic migraine in adults.
Drug patent challenges can be filed against Nurtec Odt from February, 2024.
The generics of Nurtec Odt are possible to be released after 25 March, 2039.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8314117 | BIOHAVEN IRELAND | CGRP receptor antagonists |
Feb, 2031
(8 years from now) | |
| US8759372 | BIOHAVEN IRELAND | N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt |
Feb, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11083724 | BIOHAVEN IRELAND | Rimegepant for CGRP related disorders |
Mar, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 27, 2025 |
| New Indication (I) | May 27, 2024 |
Drugs and Companies using RIMEGEPANT SULFATE ingredient
NCE-1 date: February, 2024
Market Authorisation Date: 27 February, 2020
Treatment: Acute treatment of migraine with or without aura in adults; Preventive treatment of episodic migraine in adults
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic